Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. The Company immediately initiated commercialization activities through its generic division. This is the 13^th generic product launched in 2015 by Impax's generic division.

According to IMS Health (NSP), U.S. brand and generic sales of dutasteride capsules, 0.5 mg were approximately $457 million for the 12 months ending in September 2015.